Arvinas, Inc. cash flow statement
In fiscal 2025, Arvinas, Inc.'s operations generated −$274m of cash; it spent $1.9m on capital projects, leaving free cash flow of −$276m. It returned $91.9m through buybacks.
Cash flow statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5 | −16 | −41 | −90 | 559 | −274 | −348 | −259 | −274 | −207 |
| Depreciation and amortisation | 0 | 1 | 2 | 3 | 5 | 6 | 5 | 5 | 3 | 3 |
| Stock-based pay | 0 | 12 | 20 | 30 | 57 | 76 | 72 | 88 | 44 | 37 |
| Capital spending | 1 | 3 | 6 | 6 | 5 | 7 | 3 | 2 | 2 | 2 |
| Free cash flow | 4 | −19 | −47 | −96 | 555 | −280 | −351 | −261 | −276 | −209 |
| Free cash flow after stock pay | 4 | −31 | −67 | −126 | 498 | −356 | −422 | −349 | −320 | −245 |
| Share buybacks | — | — | — | — | — | — | 0 | 0 | 92 | — |
| Shares issued | 0 | 115 | 138 | — | 1,300 | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −128 | −84 | −89 | −95 | −59 | −30 | −69 | −48 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 25 | 23 | 15 | 10 | 10 | 9 | 12 | 6 |
| Capital spending | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Free cash flow | −129 | −84 | −89 | −97 | −59 | −31 | −71 | −49 |
| Free cash flow after stock pay | −153 | −108 | −104 | −107 | −69 | −39 | −83 | −54 |
Compare with peers
- Iovance Biotherapeutics, Inc. cash flow
- Adaptive Biotechnologies Corp cash flow
- Vericel Corp cash flow
- Vir Biotechnology, Inc. cash flow
- Syndax Pharmaceuticals Inc cash flow
Head to head: ARVN vs IOVAADPT vs ARVNARVN vs VCELARVN vs VIR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies